Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582.

Experts say clinicians struggle for time to support clinical studies, limiting the scope of progress from regulatory revisions.

Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis ...

At the CTO West Coast conference, experts discussed the future of oncology clinical trials and key themes surrounding them.